Novartis AG experienced positive upward momentum accompanied by heightened intraday volatility as market participants reacted to the company’s strong financial performance and favorable earnings outlook. The primary driver behind the stock’s advance stems from core earnings per share topping consensus estimates, underpinned by robust expansion in operating margins. High-growth key commercial therapies, most notably Kisqali, Kesimpta, Scemblix, and Leqvio, delivered resilient volume expansion. This strong product portfolio performance effectively reassured investors of the pharmaceutical giant’s ability to offset revenue headwinds caused by generic competition against older legacy blockbusters.

Further strengthening institutional…